FLJ36644 inhibitors refer to a class of chemical compounds that target the protein encoded by the *FLJ36644* gene, which is associated with various cellular pathways. These inhibitors function by interacting with the structure or active sites of the protein, thereby modulating its activity within the cell. *FLJ36644* is a gene of interest due to its role in regulating intracellular processes such as signal transduction, gene expression, or protein-protein interactions. By inhibiting the protein product of this gene, the associated compounds aim to disrupt its normal function, which could lead to altered cell behavior. The inhibitors often possess specific structural features that allow them to bind selectively to the target protein, preventing it from carrying out its typical biological functions.
The development and study of FLJ36644 inhibitors often focus on the specificity and potency of these compounds in modulating the targeted protein's function. Their design typically involves high-throughput screening or rational drug design approaches, with the goal of identifying molecules that can effectively bind to the protein of interest with minimal off-target effects. Chemical properties such as solubility, stability, and binding affinity are critical in determining the efficacy of FLJ36644 inhibitors. Understanding the structural and biochemical characteristics of these inhibitors helps to elucidate how they interact with the target protein and their potential impact on cellular processes. The inhibitors may also undergo structural modifications to enhance their binding efficiency and selectivity toward the *FLJ36644*-encoded protein.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially altering PI3K/Akt signaling pathways that FLJ36644 may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK1/2, possibly affecting the MAPK/ERK pathway if FLJ36644 is associated with this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which may disrupt signaling pathways involving FLJ36644 if it is part of the mTOR pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, potentially influencing the p38 MAPK stress response pathway linked with FLJ36644. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially affecting the JNK signaling pathway if FLJ36644 is a component of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK, potentially affecting the MAPK/ERK pathway and consequently FLJ36644 if it is involved in this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Inhibits Src-family tyrosine kinases, potentially modulating signaling cascades that include FLJ36644. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits BCR-ABL and Src-family kinases, potentially altering pathways that involve FLJ36644. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Inhibits EGFR tyrosine kinase, potentially affecting signaling through pathways involving FLJ36644. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Inhibits the proteasome, potentially disrupting protein degradation pathways involving FLJ36644. | ||||||